Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Drugs
Published in:

28-09-2024 | Semaglutide | Leading Article

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy

Author: André J. Scheen

Published in: Drugs | Issue 11/2024

Login to get access

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and observational real-life studies. Besides improving glucose control, reducing body weight, and lowering arterial blood pressure (surrogate endpoints), the breakthroughs were the demonstration of a significant reduction in cardiovascular and renal events in patients with type 2 diabetes at high risk. GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure. The most striking protective effects of SGLT2is were a marked reduction in hospitalization for heart failure and a remarkable reduced progression of chronic kidney disease. These benefits have been attributed to numerous pleiotropic effects beyond glucose-lowering action. Underlying mechanisms contributing to cardiovascular and renal protection are at least partially different between GLP-1RAs (mainly anti-atherogenic and vascular effects) and SGLT2is (mainly systemic and intrarenal hemodynamic changes). Thus, patients at high risk may benefit from complementary actions when being treated with a GLP-1RA/SGLT2i combination. Such combination has proven its efficacy on surrogate endpoints. Furthermore, post hoc subgroup analyses of cardiovascular outcome trials have suggested a greater cardiorenal protection in patients treated with a combination versus either monotherapy. The benefits of a combined therapy have been confirmed in a few retrospective cohort studies. A dedicated prospective trial comparing a combined therapy versus either monotherapy is ongoing (PRECIDENTD); however, several challenges still remain, especially the higher cost of a combined therapy and the worldwide underuse of either GLP-1RAs or SGLT2is in clinical practice, even in patients at high cardiorenal risk.
Literature
1.
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2021;402:203–34.
2.
Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021;396:2019–82.PubMedCrossRef
3.
4.
Ye J, Wu Y, Yang S, et al. The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne). 2023;14:1192629.PubMedCrossRef
5.
Abushanab D, Marquina C, Morton JI, et al. Projecting the health and economic burden of cardiovascular disease among people with type 2 diabetes, 2022–2031. Pharmacoeconomics. 2023;41:719–32.PubMedPubMedCentralCrossRef
6.
Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46: 101102.PubMedCrossRef
7.
Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol. 2020;16:556–77.CrossRef
8.
Scheen AJ. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Rev Endocrinol Metab. 2023;18:271–82.PubMedCrossRef
9.
Karagiannis T, Tsapas A, Bekiari E, et al. A methodological framework for meta-analysis and clinical interpretation of subgroup data: the case of major adverse cardiovascular events with GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes. Diabetes Care. 2024;47:184–92.PubMedCrossRef
10.
Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2018;143:88–100.PubMedCrossRef
11.
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573.PubMedPubMedCentralCrossRef
12.
Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. Cardiovasc Diabetol. 2021;20:205.PubMedPubMedCentralCrossRef
13.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109–21.PubMedCrossRef
14.
Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058–66. PubMedPubMedCentralCrossRef
15.
Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Metab. 2022;48: 101390.PubMedCrossRef
16.
Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes Metab. 2022;48: 101405.PubMedCrossRef
17.
Scheen AJ. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke? Discordance between randomised controlled trials and observational studies. Diabetes Metab. 2023;49: 101474.PubMedCrossRef
18.
Caruso I, Cignarelli A, Sorice GP, et al. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites. 2022;12:183.PubMedPubMedCentralCrossRef
19.
Forbes AK, Suckling RJ, Hinton W, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:2310–30.PubMedCrossRef
20.
Hinton W, Ansari AS, Whyte MB, et al. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:501–15.PubMedCrossRef
21.
22.
Rowlands J, Heng J, Newsholme P, et al. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne). 2018;9:672.PubMedCrossRef
23.
24.
25.
26.
Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals (Basel). 2023;16:836.PubMedCrossRef
27.
Yau K, Odutayo A, Dash S, et al. Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection. Can J Cardiol. 2023;39:1816–38.PubMedCrossRef
28.
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–25.PubMedCrossRef
29.
Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10:1771–92.PubMedPubMedCentralCrossRef
30.
Ojha U, Reyes L, Eyenga F, et al. Diabetes, heart failure and beyond: elucidating the cardioprotective mechanisms of sodium glucose cotransporter 2 (SGLT2) inhibitors. Am J Cardiovasc Drugs. 2022;22:35–46.PubMedCrossRef
31.
Rastogi A, Januzzi JL Jr. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease. J Clin Med. 2023;12:2824.PubMedPubMedCentralCrossRef
32.
Preda A, Montecucco F, Carbone F, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120:443–60.PubMedCrossRef
33.
34.
Sohn M, Dietrich JW, Nauck MA, et al. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study. Cardiovasc Diabetol. 2023;22:153.PubMedPubMedCentralCrossRef
35.
Sacre JW, Magliano DJ, Shaw JE. Clinical utility of cardiovascular risk scores for identification of people with type 2 diabetes more likely to benefit from either GLP-1 receptor agonist or SGLT2 inhibitor therapy. Diabetes Care. 2022;45:1900–6.PubMedCrossRef
36.
Cardoso P, Young KG, Nair ATN, et al. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia. 2024;67:822–36.PubMedPubMedCentralCrossRef
37.
38.
Gourdy P, Darmon P, Dievart F, et al. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22:79.PubMedPubMedCentralCrossRef
39.
Cheng AYY. Why choose between SGLT2 inhibitors and GLP1-RA when you can use both?: The time to act is now. Circulation. 2021;143:780–2.PubMedCrossRef
40.
41.
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62.PubMedCrossRef
42.
Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146:1882–94.PubMedCrossRef
43.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32.PubMedCrossRef
44.
Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab. 2017;43(Suppl 1):2S13–9.PubMedCrossRef
45.
Khan MS, Fonarow GC, McGuire DK, et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation. 2020;142:1205–18.PubMedCrossRef
46.
Villaschi A, Ferrante G, Cannata F, et al. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin Res Cardiol. 2024;113:898–909.PubMedCrossRef
47.
Barbagelata L, Masson W, Lobo M, et al. Semaglutide and heart failure: updated meta-analysis. Curr Probl Cardiol. 2024;49: 102721.PubMedCrossRef
48.
Granata A, Maccarrone R, Anzaldi M, et al. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clin Kidney J. 2022;15:1657–65.PubMedPubMedCentralCrossRef
49.
Yuan D, Sharma H, Krishnan A, et al. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2022;24:1869–81.PubMedPubMedCentralCrossRef
50.
Simental-Mendia M, Linden-Torres E, Sanchez-Garcia A, et al. Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022;88:3566–76.PubMedCrossRef
51.
Alkhezi OS, Alsuhaibani HA, Alhadyab AA, et al. Heart failure outcomes and glucagon-like peptide-1 receptor agonists: a systematic review of observational studies. Prim Care Diabetes. 2021;15:761–71.PubMedCrossRef
52.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.PubMedCrossRef
53.
Delanaye P, Scheen AJ. Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin Pharmacother. 2019;20:277–94.PubMedCrossRef
54.
Scheen AJ, Delanaye P. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Rev Endocrinol Metab. 2022;17:35–46.PubMedCrossRef
55.
Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep. 2019;21:70.PubMedCrossRef
56.
Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab. 2018;44:457–64.PubMedCrossRef
57.
McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148–58.PubMedCrossRef
58.
Ali MU, Mancini GBJ, Fitzpatrick-Lewis D, et al. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23:72.PubMedPubMedCentralCrossRef
59.
Li CX, Liang S, Gao L, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS ONE. 2021;16: e0244689.PubMedPubMedCentralCrossRef
60.
Khat DZ, Husain M. Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA. Curr Diabetes Rep. 2018;18:45.CrossRef
61.
Fadah K, Alashi A, Deoker A. The enhanced cardiac outcome of conjugated SGLT2 inhibitors and GLP-1RA therapy in diabetic patients. Curr Cardiol Rep. 2022;24:17–22.PubMedCrossRef
62.
Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–16.PubMedCrossRef
63.
Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356–67.PubMedCrossRef
64.
Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370–81.PubMedCrossRef
65.
Lajara R. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgrad Med. 2019;131:555–65.PubMedCrossRef
66.
Castellana M, Cignarelli A, Brescia F, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Sci Rep. 2019;9:19351.PubMedPubMedCentralCrossRef
67.
Patoulias D, Stavropoulos K, Imprialos K, et al. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2019;158: 107927.PubMedCrossRef
68.
Zhou Y, Geng Z, Wang X, et al. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. Diabetes Metab Res Rev. 2020;36:e3223.PubMedCrossRef
69.
Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22:1857–68.PubMedCrossRef
70.
Guo M, Gu J, Teng F, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine. 2020;67:294–304.PubMedCrossRef
71.
Li C, Luo J, Jiang M, et al. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 838277.PubMedPubMedCentralCrossRef
72.
Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol. 2022;14:329–42.PubMedPubMedCentralCrossRef
73.
Ahmad A, Sabbour H. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovasc Diabetol. 2024;23:99.PubMedPubMedCentralCrossRef
74.
Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes, Obes Metab. 2016;18:82–91.PubMedCrossRef
75.
76.
Du L, Qin J, Wang D, et al. Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Front Physiol. 2022;13:1028486.PubMedPubMedCentralCrossRef
77.
Vernstrom L, Gullaksen S, Sorensen SS, et al. Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial. Diabetes Obes Metab. 2024;26:1624–35.PubMedCrossRef
78.
Lunati ME, Cimino V, Bernasconi D, et al. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacol Res. 2024;199: 107040.PubMedCrossRef
79.
Cersosimo E, Alatrach M, Solis-Herrera C, et al. Emergence of a new glucoregulatory mechanism for glycemic control with dapagliflozin/exenatide therapy in type 2 diabetes. J Clin Endocrinol Metab. 2023;109:161–70.PubMedCrossRef
80.
Iqbal N, Ambery P, Logue J, et al. Perspectives in weight control in diabetes—SGLT2 inhibitors and GLP-1-glucagon dual agonism. Diabetes Res Clin Pract. 2023;199: 110669.PubMedCrossRef
81.
Bechlioulis A, Markozannes G, Chionidi I, et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study. J Diabetes Complicat. 2023;37: 108436.CrossRef
82.
van Ruiten CC, Smits MM, Kok MD, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21:63.PubMedPubMedCentralCrossRef
83.
Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545–57.PubMedCrossRef
84.
Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019;18:138.PubMedPubMedCentralCrossRef
85.
Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145:565–74.PubMedCrossRef
86.
Neves JS, Borges-Canha M, Vasques-Novoa F, et al. GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. J Am Coll Cardiol. 2023;82:517–25.PubMedCrossRef
87.
Arnott C, Neuen BL, Heerspink HJL, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020;318:126–9.PubMedCrossRef
88.
Cahn A, Wiviott SD, Mosenzon O, et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021;23:29–38.PubMedCrossRef
89.
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35.PubMedCrossRef
90.
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–39.PubMedCrossRef
91.
Jensen MH, Kjolby M, Hejlesen O, et al. Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: a cohort study of all Danish users. Diabetes Care. 2020;43:1209–18.PubMedCrossRef
92.
Riley DR, Essa H, Austin P, et al. All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab. 2023;25:2897–909.PubMedCrossRef
93.
Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022;45:909–18.PubMedCrossRef
94.
Simms-Williams N, Treves N, Yin H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024;385: e078242.PubMedPubMedCentralCrossRef
95.
Dave CV, Kim SC, Goldfine AB, et al. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation. 2021;143:770–9.PubMedCrossRef
96.
Marfella R, Prattichizzo F, Sardu C, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23:10.PubMedPubMedCentralCrossRef
97.
Lopez PD, Bhatia K, Bohra C, et al. Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure. Am J Cardiol. 2022;181:87–93.PubMedCrossRef
98.
Belli M, Barone L, Bellia A, et al. Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients? Int J Mol Sci. 2022;23:14598.PubMedPubMedCentralCrossRef
99.
Clegg LE, Heerspink HJL, Penland RC, et al. Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL. Diabetes Care. 2019;42:318–26.PubMedCrossRef
100.
Sivalingam S, Wasehuus VS, Rotbain Curovic V, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26:54–64.PubMedCrossRef
101.
van Ruiten CC, van der Aart-van der Beek AB, RG IJ, et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021;23:1851–58.
102.
van der Aart-van der Beek AB, Apperloo E, Jongs N, et al. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study. Diabetes Obes Metab. 2023;25:1758–68.PubMedCrossRef
103.
Scheen AJ, Delanaye P. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors : a comprehensive review with a special reference to RAAS blockers. Diabetes Metab. 2022;48: 101315.PubMedCrossRef
104.
Delanaye P, Scheen AJ. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: a meta-analysis of observational cohort studies. Diabetes Epidemiol Manag. 2021;3: 100021.CrossRef
105.
Kobayashi K, Toyoda M, Tone A, et al. Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication. Diabetes Vasc Dis Res. 2023;20:14791641231222836.CrossRef
106.
Muta Y, Kobayashi K, Toyoda M, et al. Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study. Front Pharmacol. 2024;15:1358573.PubMedPubMedCentralCrossRef
107.
Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8:179–91.PubMedCrossRef
108.
Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24:1703.PubMedPubMedCentralCrossRef
109.
Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213–23.PubMedCrossRef
110.
Jang H, Kim Y, Lee DH, et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Internal Med. 2024;184:375–83.CrossRef
111.
Moon JS, Hong JH, Jung YJ, et al. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2022;33:424–42.PubMedCrossRef
112.
Ishikawa T, Terai N, Sato R, et al. Clinical efficacy and body composition changes with sodium glucose cotransporter 2 inhibitor/glucagon-like peptide-1 agonist combination therapy in patients with type 2 diabetes mellitus-associated nonalcoholic fatty liver disease. Intern Med. 2024;63:2491–7.
113.
Patoulias D, Michailidis T. SGLT-2 inhibitor and GLP-1 receptor agonist treatment for patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: is their combination the optimal treatment option? J Clin Transl Hepatol. 2022;10:574–6.PubMedPubMedCentralCrossRef
114.
115.
Consoli A, Formoso G, Baldassarre MPA, et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf. 2018;17:293–302.PubMedCrossRef
116.
Scheen AJ. Clinical pharmacology of antidiabetic drugs: what can be expected of their use? Presse Med. 2023;52: 104158.PubMedCrossRef
117.
Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175:1392–400.PubMedPubMedCentralCrossRef
118.
Morton JI, Marquina C, Shaw JE, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66:642–56.PubMedCrossRef
119.
Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94.PubMedCrossRef
120.
Wang MT, Bolland MJ, Grey A. Reporting of limitations of observational research. JAMA Intern Med. 2015;175:1571–2.PubMedCrossRef
121.
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66.PubMedPubMedCentralCrossRef
122.
ElSayed NA, Aleppo G, Aroda VR, et al. Erratum. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S158–90.PubMedCrossRef
123.
Marx N, Federici M, Schutt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140.PubMedCrossRef
124.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:e895–1032.PubMed
125.
Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117–314.CrossRef
126.
Scheen AJ. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favourable benefit-safety profile. Expert Opin Drug Saf. 2024;23:797–810.PubMedCrossRef
127.
Scheen AJ. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manag. 2024;13: 100184.CrossRef
128.
Scheen AJ. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease. Diabetes Epidemiol Manag. 2024;14: 100197.CrossRef
129.
Scheen AJ. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized? Expert Rev Clin Pharmacol. 2023;16:1053–62.PubMedCrossRef
130.
Scheen AJ. Add-on value of tirzepatide versus semaglutide. Lancet Diabetes Endocrinol. 2022;10:377–8.PubMedCrossRef
131.
Scheen AJ. Dual GIP/GLP-1 receptor agonists : new advance for treating type 2 diabetes. Ann Endocrinol. 2023;84:316–21.CrossRef
132.
133.
Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583–98.PubMedCrossRef
134.
Jakubowska A, Roux CWL, Viljoen A. The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor—an update. Endocrinol Metab (Seoul). 2024;39:12–22.PubMedCrossRef
135.
Zhang Y, Jiang L, Wang J, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21:232.PubMedPubMedCentralCrossRef
136.
Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149:450–62.PubMedCrossRef
Metadata
Title
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
Author
André J. Scheen
Publication date
28-09-2024
Publisher
Springer International Publishing
Published in
Drugs / Issue 11/2024
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02090-9

Other articles of this Issue 11/2024

Vunakizumab: First Approval

Seladelpar: First Approval

Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders

Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now

Axatilimab: First Approval

Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials